Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 59

1.

Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.

Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Santos J, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S; GESIDA 7011 Study Group.

Lancet Infect Dis. 2015 Jul;15(7):775-84. doi: 10.1016/S1473-3099(15)00097-3. Epub 2015 Jun 7.

PMID:
26062881
2.

Prevalence of hepatitis C antibodies in the population aged 16-80 years in the Community of Madrid 2008-2009.

García Comas L, Ordobás Gavín M, Sanz Moreno JC, Ramos Blázquez B, Gutiérrez Rodríguez A, Astray Mochales J, Moreno Guillén S.

J Med Virol. 2015 May 18. doi: 10.1002/jmv.24219. [Epub ahead of print]

PMID:
25989026
3.

Seroprevalence of measles and rubella virus antibodies in the population of the Community of Madrid, 2008-2009.

García-Comas L, Sanz Moreno JC, Ordobás Gavín M, Barranco Ordóñez D, García Gutiérrez J, Ramos Blázquez B, Rodero Garduño I.

J Infect Public Health. 2015 May 6. pii: S1876-0341(15)00048-9. doi: 10.1016/j.jiph.2015.01.012. [Epub ahead of print]

PMID:
25957894
4.

Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study.

Carrero-Gras A, Antela A, Muñoz-Rodríguez J, Díaz-Menéndez M, Viciana P, Torrella-Domingo A, Sanz-Moreno J, Téllez-Molina MJ, Moreno J, Hernández-Quero J, Pérez-Hernández IA, Domingo-Pedrol P.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19819. doi: 10.7448/IAS.17.4.19819. eCollection 2014.

5.

Efficacy and tolerability of telaprevir (TVR)-based triple therapy in HIV/HCV-coinfected patients.

De Los Santos I, Montes M, Sanz-Moreno J, De Miguel J, Sanz-Sanz J, Gaspar G, Perez-Caballero L.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19633. doi: 10.7448/IAS.17.4.19633. eCollection 2014.

6.

Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008-2011.

Gutierrez Rodriguez MA, Ordobas Gavin MA, Garcia-Comas L, Sanz Moreno JC, Cordoba Deorador E, Lasheras Carbajo MD, Taveira Jimenez JA, Martin Martinez F, Iniesta Fornies D, Arce Arnaez A.

Euro Surveill. 2014 Oct 9;19(40):20922.

7.

Hepatitis B virus infection and vaccine-induced immunity in Madrid (Spain).

Pedraza-Flechas AM, García-Comas L, Ordobás-Gavín M, Sanz-Moreno JC, Ramos-Blázquez B, Astray-Mochales J, Moreno-Guillén S.

Gac Sanit. 2014 Nov-Dec;28(6):492-5. doi: 10.1016/j.gaceta.2014.05.007. Epub 2014 Jul 18.

8.

Reducing major lower extremity amputations after the introduction of a multidisciplinary team for the diabetic foot.

Rubio JA, Aragón-Sánchez J, Jiménez S, Guadalix G, Albarracín A, Salido C, Sanz-Moreno J, Ruiz-Grande F, Gil-Fournier N, Álvarez J.

Int J Low Extrem Wounds. 2014 Mar;13(1):22-6. doi: 10.1177/1534734614521234.

PMID:
24659624
9.

Incidence of hepatocellular carcinoma in HIV-infected patients with cirrhosis: a prospective study.

Montes Ramírez ML, Miró JM, Quereda C, Jou A, von Wichmann MÁ, Berenguer J, González-García JJ, Hernando A, Ortega E, Sanz J, Arribas JR; GESIDA 3703.FIPSE 36466503-N5 NEAT Study Group.

J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):82-6. doi: 10.1097/QAI.0b013e3182a685dc.

PMID:
24419065
10.

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.

Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G; SINGLE Investigators.

N Engl J Med. 2013 Nov 7;369(19):1807-18. doi: 10.1056/NEJMoa1215541.

11.

Risk factors and clinical significance of invasive infections caused by levofloxacin-resistant Streptococcus pneumoniae.

Isea-Peña MC, Sanz-Moreno JC, Esteban J, Fernández-Roblas R, Fernández-Guerrero ML.

Infection. 2013 Oct;41(5):935-9. doi: 10.1007/s15010-013-0481-4. Epub 2013 May 25.

PMID:
23709294
12.

Efficacy and safety of nevirapine + Kivexa (abacavir/lamivudine) as a simplification strategy for HIV patients with undetectable viral load.

Cabello Úbeda A, Sanz Moreno J, Williams F, Górgolas M.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):e95-6. doi: 10.1097/QAI.0b013e31822ccfe3. No abstract available.

PMID:
22005001
13.
14.

The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients.

López-Diéguez M, Montes ML, Pascual-Pareja JF, Quereda C, Von Wichmann MA, Berenguer J, Tural C, Hernando A, González-García J, Serrano L, Arribas JR; GESIDA 37/03-FIPSE 36465/03-NEAT IG5 Study Group.

AIDS. 2011 Apr 24;25(7):899-904. doi: 10.1097/QAD.0b013e3283454174.

PMID:
21330908
15.

Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen.

Ghosn J, Carosi G, Moreno S, Pokrovsky V, Lazzarin A, Pialoux G, Sanz-Moreno J, Balogh A, Vandeloise E, Biguenet S, Leleu G, Delfraissy JF.

Antivir Ther. 2010;15(7):993-1002. doi: 10.3851/IMP1666.

PMID:
21041914
16.

Minimal removal of raltegravir by hemodialysis in HIV-infected patients with end-stage renal disease.

Moltó J, Sanz-Moreno J, Valle M, Cedeño S, Bonal J, Bouarich H, Clotet B.

Antimicrob Agents Chemother. 2010 Jul;54(7):3047-8. doi: 10.1128/AAC.00363-10. Epub 2010 May 3.

17.

[Evolution of measles, rubella and mumps from the third seroepidemiological survey in the autonomous region of Madrid, Spain].

Sanz Moreno JC, García Comas L, Ramírez Fernández R, Ramos Blázquez B, Ordobás Gavín M.

Rev Esp Salud Publica. 2009 Sep-Oct;83(5):625-37. Spanish.

18.

Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients.

Pineda JA, González J, Ortega E, Tural C, Macías J, Griffa L, Burgos A; Grafihco Study Team.

J Viral Hepat. 2010 Oct;17(10):714-9. doi: 10.1111/j.1365-2893.2009.01229.x.

PMID:
20002560
19.

Prevalence of HLA-B*5701 in HIV-infected patients in Spain (results of the EPI Study).

Arrizabalaga J, Rodriguez-Alcántara F, Castañer JL, Ocampo A, Podzamczer D, Pulido F, Riera M, Sanz J, Pascual-Bernaldez M, Dal-Re R; EPI109839 Study Group.

HIV Clin Trials. 2009 Jan-Feb;10(1):48-51. doi: 10.1310/hct1001-048.

PMID:
19362996
20.

Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.

Pérez-Elias MJ, Sánchez-Conde M, Soriano V, Mallolas J, Luque I, Rodríguez-Alcántara F; Fosamprenavir Expanded Access Program Group.

Enferm Infecc Microbiol Clin. 2009 Jan;27(1):28-32. doi: 10.1016/j.eimc.2008.05.002. Epub 2009 Jan 9.

PMID:
19218000
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk